Dyslipidemia resident survival guide: Difference between revisions
YazanDaaboul (talk | contribs) |
YazanDaaboul (talk | contribs) |
||
Line 126: | Line 126: | ||
{{familytree | |,|-|-|-|+|-|-|-|.| | | |,|-|-|-|+|-|-|-|.| | | | | | | | | | | | | | | | | | | | |}} | {{familytree | |,|-|-|-|+|-|-|-|.| | | |,|-|-|-|+|-|-|-|.| | | | | | | | | | | | | | | | | | | | |}} | ||
{{familytree | K01 | | K02 | | K03 | | K04 | | K05 | | K06 | | | | | | | | | | | | | | | | | | | |K01=Age 20 | {{familytree | K01 | | K02 | | K03 | | K04 | | K05 | | K06 | | | | | | | | | | | | | | | | | | | |K01=Age between 20 and 45 years|K02=Age > 45 years to 65 years|K03=Age > 65 years|K04=Age between 20 years and 55 years|K05=Age > 55 years to 65 years|K06=Age > 65 years}} | ||
{{familytree | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | | | | | | | | | | | | | | | | | | | |}} | {{familytree | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | | | | | | | | | | | | | | | | | | | |}} |
Revision as of 15:53, 20 April 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Classification
Causes
Secondary causes of dyslipidemia may cause either an increase in total-cholesterol & low density lipoprotein-cholesterol (LDL-C) or an increase in total triglycerides & very low density lipoprotein cholesterol (VLDL-C). Common causes are listed below.
Increase in Total Cholesterol and LDL-C
- Hypothyroidism
- Nephrosis
- Dysgammaglobulinemia (systemic lupus erythematosus, multiple myeloma)
- Cholestatic hepatic diseases due to abnormal lipoproteins (e.g. primary biliary cirrhosis)
- Administration of protease inhibitors (treatment for HIV infection)
- Administration of progestin or anabolic steroids
Increase in Total Triglycerides and VLDL-C
- Chronic kidney disease
- Type 2 diabetes mellitus
- Obesity
- Excessive alcohol intake
- Hypothyroidism
- Administration of anti-hypertensive therapy (thiazide diuretics or B-blockers)
- Administration of corticosteroids
- Severe stress that increases endogenous corticosteroid concentration
- Elevated concentrations of estrogen (administration of oral (not transdermal) estrogen therapy, oral contraceptives, or pregnancy)
- Administration of protease inhibitors (treatment for HIV infection)
To view a comprehensive list of dyslipidemia causes, click here
Screening
Abbreviations: ASA: American society of anesthesiologists; BP: Blood Pressure; CCS: Canadian cardiovascular society; CrCl: Creatinine clearance; CXR: Chest X-ray; DNI: Do not intubate; DNR: Do not resuscitate; ECG: Electrocardiogram; eGFR: estimated glomerular filtration rate; HR:Heart rate; INR: International normalized ratio; LMWH: Low molecular weight heparin; LV: Left ventricle; LVED: Left ventricular ejection fraction; NOAC: Novel oral anticoagulant; NPO: Nothing per os; PMI: Point of maximal impulse; PT: Prothrombin time; RR: Respiratory rate; SpO2: Oxygen saturation; T: Temperature; VT: Ventricular tachycardia
Identify risk factors for CAD Major risk factors: ❑ Advanced age ❑ ↑ total serum cholesterol ❑ ↑ non-HDL-C (calculated by: total cholesterol minus HDL-C) ❑ ↑ LDL-C (either measured or calculated by: total cholesterol minus HDL-c minus (total triglycerides/5)) ❑ ↓ HDL-C ❑ Diabetes mellitus ❑ Hypertension ❑ Cigarette smoking ❑ Family history of CAD ❑ Obesity, especially abdominal ❑ Family history of hyperlipidemia ❑ Small, dense LDL-C ❑ ↑ Apo-B ❑ ↑ LDL particle number (measured by ApoB) ❑ Fasting/postprandial hypertriglyceridemia ❑ Polycystic ovarian syndrome ❑ Dyslipidemic triad ❑ ↑ lipoprotein ❑ ↑ clotting factors ❑ Inflamamtory markers (e.g. hsCRP or Lipoprotein-associated phospholipase A2 (Lp-PLA2) ❑ Hyperhomocysteinemia ❑ ApoE4 isoform | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
High (Framingham 10-year global risk > 20%) | Intermediate (Framingham 10-year global risk between 10% and 20%) | Lower (Framingham 10-year global risk < 10%) | Optimal (Framingham 10-year global risk < 10% with optimal levels or risk factors and heart-healthy lifestyle) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Does the patient have type 2 diabetes mellitus? | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Does the patient have ALL the following criteria for low-risk dyslipidemia during previous work-up? ❑ Low LDL-C < 100 mg/dL, AND ❑ HDL-C > 50 mg/dL, AND | Adult patient | Pediatric patient (age at least 2 years) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes. The patient has ALL of the criteria for low-risk dyslipidemia | Either unknown history of lipid profile or No, the patient does not have ALL of the criteria for low-risk dyslipidemia (at least 1 criterion is not met) | Does that patient have risk factors for CAD (listed above)? | Does the patient have risk factors for CAD (listed above)? | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Screen every 2 years | Screen annually | No | Yes | Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Screen patient more frequently than patients with no risk factors based on clinical judgement (unknown optimal interval) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Male patient | Female patient | Screen every 3 to 5 years | Do not screen patient for dyslipidemia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Age between 20 and 45 years | Age > 45 years to 65 years | Age > 65 years | Age between 20 years and 55 years | Age > 55 years to 65 years | Age > 65 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Screen every 5 years More frequent screening is recommended for patients with risk factors for CAD (shown above) | Screen every 1 to 2 years More frequent screening is recommended for patients with risk factors for CAD (shown above) | Screen annually | Screen every 5 years More frequent screening is recommended for patients with risk factors for CAD (shown above) | Screen every 1 to 2 years More frequent screening is recommended for patients with risk factors for CAD (shown above) | Screen annually | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||